Literature DB >> 16083281

Quantitative protein expression analysis of CLL B cells from mutated and unmutated IgV(H) subgroups using acid-cleavable isotope-coded affinity tag reagents.

David R Barnidge1, Diane F Jelinek, David C Muddiman, Neil E Kay.   

Abstract

Relative protein expression levels were compared in leukemic B cells from two patients with chronic lymphocytic leukemia (CLL) having either mutated (M-CLL) or unmutated (UM-CLL) immunoglobulin variable heavy chain genes (IgV(H)). Cells were separated into cytosol and membrane protein fractions then labeled with acid-cleavable ICAT reagents (cICAT). Labeled proteins were digested with trypsin then subjected to SCX and affinity chromatography followed by LC-ESI-MS/MS analysis on a linear ion trap mass spectrometer. A total of 9 proteins from the cytosol fraction and 4 from the membrane fraction showed a 3-fold or greater difference between M-CLL and UM-CLL and a subset of these were examined by Western blot where results concurred with cICAT abundance ratios. The abundance of one of the proteins in particular, the mitochondrial membrane protein cytochrome c oxidase subunit COX G was examined in 6 M-CLL and 6 UM-CLL patients using western blot and results showed significantly greater levels (P < 0.001) in M-CLL patients vs UM-CLL patients. These results demonstrate that stable isotope labeling and mass spectrometry can complement 2D gel electrophoresis and gene microarray technologies for identifying putative and perhaps unique prognostic markers in CLL.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16083281      PMCID: PMC1403294          DOI: 10.1021/pr050028f

Source DB:  PubMed          Journal:  J Proteome Res        ISSN: 1535-3893            Impact factor:   4.466


  21 in total

1.  An accurate mass tag strategy for quantitative and high-throughput proteome measurements.

Authors:  Richard D Smith; Gordon A Anderson; Mary S Lipton; Ljiljana Pasa-Tolic; Yufeng Shen; Thomas P Conrads; Timothy D Veenstra; Harold R Udseth
Journal:  Proteomics       Date:  2002-05       Impact factor: 3.984

2.  Analysis of clonal B-cell CD38 and immunoglobulin variable region sequence status in relation to clinical outcome for B-chronic lymphocytic leukaemia.

Authors:  D F Jelinek; R C Tschumper; S M Geyer; N D Bone; G W Dewald; C A Hanson; M J Stenson; T E Witzig; A Tefferi; N E Kay
Journal:  Br J Haematol       Date:  2001-12       Impact factor: 6.998

Review 3.  Prognosis at diagnosis: integrating molecular biologic insights into clinical practice for patients with CLL.

Authors:  Tait D Shanafelt; Susan M Geyer; Neil E Kay
Journal:  Blood       Date:  2003-10-23       Impact factor: 22.113

4.  Proteomic analysis of chronic lymphocytic leukemia subtypes with mutated or unmutated Ig V(H) genes.

Authors:  Duncan A E Cochran; Caroline A Evans; David Blinco; John Burthem; Freda K Stevenson; Simon J Gaskell; Anthony D Whetton
Journal:  Mol Cell Proteomics       Date:  2003-10-13       Impact factor: 5.911

5.  Protein expression profiling of CLL B cells using replicate off-line strong cation exchange chromatography and LC-MS/MS.

Authors:  David R Barnidge; Renee C Tschumper; Diane F Jelinek; David C Muddiman; Neil E Kay
Journal:  J Chromatogr B Analyt Technol Biomed Life Sci       Date:  2005-05-05       Impact factor: 3.205

6.  Mitochondrial proteome: altered cytochrome c oxidase subunit levels in prostate cancer.

Authors:  Paul C Herrmann; John W Gillespie; Lu Charboneau; Verena E Bichsel; Cloud P Paweletz; Valerie S Calvert; Elise C Kohn; Michael R Emmert-Buck; Lance A Liotta; Emanuel F Petricoin
Journal:  Proteomics       Date:  2003-09       Impact factor: 3.984

7.  Correlation of clinical data with proteomics profiles in 24 patients with B-cell chronic lymphocytic leukemia.

Authors:  T Voss; H Ahorn; P Haberl; H Döhner; K Wilgenbus
Journal:  Int J Cancer       Date:  2001-01-15       Impact factor: 7.396

8.  Proteomic analysis of the cell-surface membrane in chronic lymphocytic leukemia: identification of two novel proteins, BCNP1 and MIG2B.

Authors:  R S Boyd; P J Adam; S Patel; J A Loader; J Berry; N T Redpath; H R Poyser; G C Fletcher; N A Burgess; A C Stamps; L Hudson; P Smith; M Griffiths; T G Willis; E L Karran; D G Oscier; D Catovsky; J A Terrett; M J S Dyer
Journal:  Leukemia       Date:  2003-08       Impact factor: 11.528

9.  Mitochondrial DNA mutations in primary leukemia cells after chemotherapy: clinical significance and therapeutic implications.

Authors:  J S Carew; Y Zhou; M Albitar; J D Carew; M J Keating; Peng Huang
Journal:  Leukemia       Date:  2003-08       Impact factor: 11.528

10.  Distinctive roles of PHAP proteins and prothymosin-alpha in a death regulatory pathway.

Authors:  Xuejun Jiang; Hyun-Eui Kim; Hongjun Shu; Yingming Zhao; Haichao Zhang; James Kofron; Jennifer Donnelly; Dave Burns; Shi-Chung Ng; Saul Rosenberg; Xiaodong Wang
Journal:  Science       Date:  2003-01-10       Impact factor: 47.728

View more
  2 in total

1.  Proteomics Profiling of CLL Versus Healthy B-cells Identifies Putative Therapeutic Targets and a Subtype-independent Signature of Spliceosome Dysregulation.

Authors:  Harvey E Johnston; Matthew J Carter; Marta Larrayoz; James Clarke; Spiro D Garbis; David Oscier; Jonathan C Strefford; Andrew J Steele; Renata Walewska; Mark S Cragg
Journal:  Mol Cell Proteomics       Date:  2018-01-24       Impact factor: 5.911

2.  Total proteome analysis identifies migration defects as a major pathogenetic factor in immunoglobulin heavy chain variable region (IGHV)-unmutated chronic lymphocytic leukemia.

Authors:  Gina L Eagle; Jianguo Zhuang; Rosalind E Jenkins; Kathleen J Till; Puthen V Jithesh; Ke Lin; Gillian G Johnson; Melanie Oates; Kevin Park; Neil R Kitteringham; Andrew R Pettitt
Journal:  Mol Cell Proteomics       Date:  2015-02-02       Impact factor: 5.911

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.